2022-003318-35
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus
Vertex Pharmaceuticals Incorporated·EU Clinical Trials RegisterOngoing
Study focus
- Disease/Condition
- Type 1 Diabetes Mellitus
Sponsor & location
- Primary sponsor
- Vertex Pharmaceuticals Incorporated
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
1. Prior islet cell transplant, organ transplant, or cell therapy.
ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2022-003318-35
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2022-003318-35 through Pure Global AI's free database. This phase not specified trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently Ongoing. The study focuses on Type 1 Diabetes Mellitus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.